tetano
Editor, Senior Moderator
Vaccine
. 2026 Jul 19:88:128951.
doi: 10.1016/j.vaccine.2026.128951. Online ahead of print.
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses
Narges Ebrahimi[SUP] 1 [/SUP], Philip de Whalley[SUP] 2 [/SUP], Nasir Kanji[SUP] 1 [/SUP], Maheshi N Ramasamy[SUP] 3 [/SUP], Parvinder K Aley[SUP] 1 [/SUP], Sagida Bibi[SUP] 1 [/SUP], Elizabeth A Clutterbuck[SUP] 1 [/SUP], Andrea M Collins[SUP] 4 [/SUP], Thomas C Darton[SUP] 5 [/SUP], Christopher J A Duncan[SUP] 6 [/SUP], Saul N Faust[SUP] 7 [/SUP], Elaine Shuo Feng[SUP] 8 [/SUP], Anna L Goodman[SUP] 9 [/SUP], Christopher A Green[SUP] 10 [/SUP], Paul T Heath[SUP] 11 [/SUP], Jonathan Kwok[SUP] 1 [/SUP], Rajeka Lazarus[SUP] 12 [/SUP], Vincenzo Libri[SUP] 13 [/SUP], Patrick J Lillie[SUP] 14 [/SUP], Alastair McGregor[SUP] 15 [/SUP], Yama F Mujadidi[SUP] 1 [/SUP], Nelly Owino[SUP] 1 [/SUP], Emma Plested[SUP] 1 [/SUP], Katrina M Pollock[SUP] 16 [/SUP], Hannah Robinson[SUP] 1 [/SUP], Rebecca K Sutherland[SUP] 17 [/SUP], Emma C Thomson[SUP] 18 [/SUP], Mark Toshner[SUP] 19 [/SUP], David P J Turner[SUP] 20 [/SUP], Christopher J Williams[SUP] 21 [/SUP], Ian Hirsch[SUP] 22 [/SUP], Tonya L Villafana[SUP] 23 [/SUP], Teresa Lambe[SUP] 24 [/SUP], Merryn Voysey[SUP] 1 [/SUP], Andrew J Pollard[SUP] 1 [/SUP]
Affiliations
Rationale: Follow-up of pre-licensure trial participants potentially informs a vaccine's long-term safety profile.
Design: This prospective study enrolled participants from the first clinical trials of ChAdOx1 nCoV-19 vaccine, many of whom subsequently received COVID-19 vaccines in the UK vaccination programme. Serious adverse events (SAEs) and adverse events of special interest (AESIs) were captured. AESI selection was based on Brighton Collaboration definitions.
Results: Between September 2021 and April 2022, 4470 participants enrolled (58% female, median age 50 years); 3845/4470 (86.0%) completed the study. Median follow-up was 11.77 months; total follow-up was 48,116 person-months. There were 174 SAEs and 71 AESIs (33 events recorded as both) in 195 participants, including 5 deaths. Immunology data were available for a small subset of participants; total IgG against trimeric SARS-CoV-2 spike protein tended to increase during the study.
Conclusions: Although no emergent safety signals were detected, continued post-marketing surveillance remains imperative, particularly for neurological disorders.
Eudract number: 2021-003382-36.
Keywords: AZD1222; Adenoviral vector vaccine; Booster vaccine; Covishield; Pandemic; Vaxzevria.
. 2026 Jul 19:88:128951.
doi: 10.1016/j.vaccine.2026.128951. Online ahead of print.
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses
Narges Ebrahimi[SUP] 1 [/SUP], Philip de Whalley[SUP] 2 [/SUP], Nasir Kanji[SUP] 1 [/SUP], Maheshi N Ramasamy[SUP] 3 [/SUP], Parvinder K Aley[SUP] 1 [/SUP], Sagida Bibi[SUP] 1 [/SUP], Elizabeth A Clutterbuck[SUP] 1 [/SUP], Andrea M Collins[SUP] 4 [/SUP], Thomas C Darton[SUP] 5 [/SUP], Christopher J A Duncan[SUP] 6 [/SUP], Saul N Faust[SUP] 7 [/SUP], Elaine Shuo Feng[SUP] 8 [/SUP], Anna L Goodman[SUP] 9 [/SUP], Christopher A Green[SUP] 10 [/SUP], Paul T Heath[SUP] 11 [/SUP], Jonathan Kwok[SUP] 1 [/SUP], Rajeka Lazarus[SUP] 12 [/SUP], Vincenzo Libri[SUP] 13 [/SUP], Patrick J Lillie[SUP] 14 [/SUP], Alastair McGregor[SUP] 15 [/SUP], Yama F Mujadidi[SUP] 1 [/SUP], Nelly Owino[SUP] 1 [/SUP], Emma Plested[SUP] 1 [/SUP], Katrina M Pollock[SUP] 16 [/SUP], Hannah Robinson[SUP] 1 [/SUP], Rebecca K Sutherland[SUP] 17 [/SUP], Emma C Thomson[SUP] 18 [/SUP], Mark Toshner[SUP] 19 [/SUP], David P J Turner[SUP] 20 [/SUP], Christopher J Williams[SUP] 21 [/SUP], Ian Hirsch[SUP] 22 [/SUP], Tonya L Villafana[SUP] 23 [/SUP], Teresa Lambe[SUP] 24 [/SUP], Merryn Voysey[SUP] 1 [/SUP], Andrew J Pollard[SUP] 1 [/SUP]
Affiliations
- PMID: 42472497
- DOI: 10.1016/j.vaccine.2026.128951
Rationale: Follow-up of pre-licensure trial participants potentially informs a vaccine's long-term safety profile.
Design: This prospective study enrolled participants from the first clinical trials of ChAdOx1 nCoV-19 vaccine, many of whom subsequently received COVID-19 vaccines in the UK vaccination programme. Serious adverse events (SAEs) and adverse events of special interest (AESIs) were captured. AESI selection was based on Brighton Collaboration definitions.
Results: Between September 2021 and April 2022, 4470 participants enrolled (58% female, median age 50 years); 3845/4470 (86.0%) completed the study. Median follow-up was 11.77 months; total follow-up was 48,116 person-months. There were 174 SAEs and 71 AESIs (33 events recorded as both) in 195 participants, including 5 deaths. Immunology data were available for a small subset of participants; total IgG against trimeric SARS-CoV-2 spike protein tended to increase during the study.
Conclusions: Although no emergent safety signals were detected, continued post-marketing surveillance remains imperative, particularly for neurological disorders.
Eudract number: 2021-003382-36.
Keywords: AZD1222; Adenoviral vector vaccine; Booster vaccine; Covishield; Pandemic; Vaxzevria.